McKesson PT receives Investment Bank Analyst Rating Update
Investing.com - McKesson (NYSE: MCK) reported third quarter EPS of $6.90, $0.54 better than the analyst estimate of $6.36. Revenue for the quarter came in at $70.49B versus the...
McKesson (MCK) reported Q3 EPS of $6.90, $0.54 better than the analyst estimate of $6.36. Revenue for the quarter came in at $70.49 billion versus the consensus estimate of $71.08...
In the past week, legendary investor Warren Buffett’s company, Berkshire Hathaway (NYSE:BRKa), submitted its first-quarter filing with the Security Exchange Commission, which...
A lot happened in the markets this past week. And perhaps the best analogy to explain it all rests with one obscure development in the broader world of economics: The price of eggs...
Warren Buffett's cash pile has reached its lowest level since 2019 The Oracle of Omaha has bought a total of 16 stocks this year Like him, I believe it is a good time to...
McKesson Corporation is a diversified healthcare services provider. The Company is focused on advancing health outcomes for patients everywhere. It operates its business through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. Its U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter (OTC) pharmaceutical drugs, and other healthcare-related products. Its Prescription Technology Solutions segment serves its biopharma and life sciences partners and patients. Its Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, nursing homes, hospital reference labs, and home health care agencies. Its International segment provides distribution and services to wholesale, institutional, and retail customers in 11 European countries and Canada.
|Average||420.58 (+16.00% Upside)|
|No. of Analysts||12|